|Previous Section||Index||Home Page|
|LCD( 1) , court service and PGO1 April 2001( 2)|
|Full-time staff||Part-time staff||Full-time equivalent|
|(1 )Lord Chancellor's Department (LCD) prior to 2003 (2) 2001 and 2002 figures do not provide a breakdown between full and part-time employees.|
|Appendix B: Magistrates courts service staff by Gender 2005|
|Data||Female||Male||Full-time total||Female||Male||Part-time total||Grand total|
Mr. Amess: To ask the Secretary of State for Health what recent discussions she has had with representatives of the medical profession about the interpretation by them of section one of the Abortion Act 1967; and if she will make a statement. 
Mr. Amess: To ask the Secretary of State for Health if she will amend the abortion notification form to provide for the inclusion of the method of abortion known as partial birth abortion; and if she will make a statement. 
Anne Main: To ask the Secretary of State for Health pursuant to the Answer of 15 May 2006, Official Report, columns 736-7W on adverse drug reactions, when she expects the redesign of the drug safety monitoring database to be completed. 
Andy Burnham: Reports of suspected adverse drug reactions (ADRs) are collected by the Medicines and Healthcare products Regulatory Agency (MHRA) and the commission on human medicines through the spontaneous reporting scheme, the yellow card scheme.
The MHRA is currently implementing a major upgrade of the drug safety monitoring database and data reporting systems. The MHRAs redesigned drug safety monitoring database was deployed on 31 May 2006.
Mr. Hancock: To ask the Secretary of State for Health what recent research she has (a) commissioned and (b) evaluated on the number of people hospitalised each year due to adverse reactions to (i) prescribed and (ii) unprescribed drugs; and if she will make a statement. 
Andy Burnham: The most recent estimate of the burden of adverse drug reactions (ADRs) in the United Kingdom (UK) comes from a study published in the British Medical Journal in July 2004. The study conducted in two large hospitals in Merseyside, suggested that ADRs account for one in 16 hospital admissions. This is a similar estimate to a number of studies worldwide, including figures from the United States. The study did not differentiate between prescribed and unprescribed medicines; however, the majority of ADRs were associated with prescribed medicines.
This study highlights the importance of effective systems for monitoring and responding to issues relating to the safety of medicines, a process called pharmacovigilance. This study, which was funded by the Medicines and Healthcare products Regulatory Agency (MHRA), underlines the MHRAs commitment to improving the evidence base for pharmacovigilance in the UK. As part of this commitment to improving pharmacovigilance, the MHRA is working to strengthen and widen access to the yellow card scheme for reporting suspected ADRs. Access has recently been widened to allow patients to report under a pilot reporting scheme.
|Next Section||Index||Home Page|